Objective-The effects of coronary perivascular adipose tissue (PVAT) on vasomotor tone are influenced by an obese phenotype and are distinct from other adipose tissue depots. The purpose of this investigation was to examine the effects of lean and obese coronary PVAT on end-effector mechanisms of coronary vasodilation and to identify potential factors involved. Approach and Results-Hematoxylin and eosin staining revealed similarities in coronary perivascular adipocyte size between lean and obese Ossabaw swine. Isometric tension studies of isolated coronary arteries from Ossabaw swine revealed that factors derived from lean and obese coronary PVAT attenuated vasodilation to adenosine. Lean coronary PVAT inhibited K Ca and K V 7, but not K ATP channel-mediated dilation in lean arteries. In the absence of PVAT, vasodilation to K Ca and K V 7 channel activation was impaired in obese arteries relative to lean arteries. Obese PVAT had no effect on K Ca or K V 7 channel-mediated dilation in obese arteries. In contrast, obese PVAT inhibited K ATP channel-mediated dilation in both lean and obese arteries. The differential effects of obese versus lean PVAT were not associated with changes in either coronary K V 7 or K ATP channel expression. Incubation with calpastatin attenuated coronary vasodilation to adenosine in lean but not in obese arteries. Conclusions-These findings indicate that lean and obese coronary PVAT attenuates vasodilation via inhibitory effects on vascular smooth muscle K + channels and that alterations in specific factors such as calpastatin are capable of contributing to the initiation or progression of smooth muscle dysfunction in obesity. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
P erivascular adipose tissue (PVAT) surrounds large arteries throughout the body and is capable of producing adipokines that act directly on the adjacent vasculature. 1, 2 PVATderived factors have been shown to stimulate chemotaxis, inflammation, and endothelial dysfunction, thereby implicating local PVAT signaling in the initiation and progression of vascular disease. [3] [4] [5] [6] [7] [8] Data from recent studies investigating vascular responses to PVAT-derived factors suggest that the endothelial and smooth muscle effects of these substances are highly dependent on anatomic location of the adipose/vascular depot and the underlying disease state of the subjects from which the tissues were obtained. 2 Such discrepant phenotypic effects of PVAT are not surprising given marked differences in protein expression and secretion profiles of adipose tissue depots from lean versus obese subjects. [9] [10] [11] [12] [13] [14] [15] However, current understanding of how these alterations influence mechanisms of vascular function remains limited.
Differences in the vascular effects of PVAT-derived factors are evident when comparing peripheral (noncardiac) versus coronary-cardiac PVAT. In particular, aortic, 16, 17 mesenteric, 18, 19 and internal thoracic artery 20, 21 PVAT have been shown to significantly diminish contractile responses to a variety of agonists. This vasodilator or anticontractile effect is attributed to production of adipose-derived relaxing factor(s) that promote endothelial dependent or independent vasodilation via activation of voltage-dependent K V 7 channels, 18 BK Ca channels, 21, 22 and K ir channels. 23 In contrast, factors released from coronary PVAT have been shown to attenuate endothelial-dependent dilation 5, 7 and potentiate coronary artery contractions. 12 These deleterious effects of coronary PVAT are augmented in the setting of obesity and are directly associated with marked alterations in the coronary PVAT proteome and the functional expression of coronary K + and Ca 2+ channels. 12, 24, 25 Specifically, our laboratory has recently demonstrated that the endogenous calpain inhibitor calpastatin 26, 27 is significantly elevated in the secreted protein expression profile of obese coronary PVAT and is sufficient to dose-dependently augment coronary artery contractions in the absence of PVAT. 12 Obesity has also been found to diminish the contribution of end-effector K + channels to coronary vasodilator responses. 28 These channels include voltage-dependent (K V ), Ca 2+ -activated (K Ca ), and ATP-sensitive (K ATP ) channels, which regulate smooth muscle membrane potential and participate in the regulation of coronary vascular resistance. 29 However, the extent to which coronary PVAT-derived factors modulate the role of these channels has not been investigated.
Accordingly, the purpose of this investigation was to delineate the effects of lean and obese coronary PVAT on endeffector mechanisms of coronary vasodilation and to identify potential PVAT-derived factors involved. Studies were specifically designed to test the hypothesis that lean and obese PVAT differentially attenuate K Ca , K V , and K ATP channel-mediated vasodilation in the coronary circulation and that calpastatin contributes to these effects. Findings from this investigation add to growing evidence supporting a role for PVAT in the pathogenesis of vascular dysfunction in obesity-induced coronary disease.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Phenotype of Lean and Obese Ossabaw Swine
Compared with their lean counterparts, obese swine exhibited significant increases in body weight, fasting glucose, total cholesterol, and triglycerides (Table 1) . Histopathologic analyses to examine the morphology of perivascular adipocytes were performed on sections of coronary arteries with the adjacent PVAT intact. Hematoxylin and eosin staining revealed apparent similarities in perivascular adipocyte size between lean ( Figure 1A ) and obese ( Figure 1B ) swine. Specifically, adipocyte diameter averaged 70±1 μm in lean and 67±2 μm in obese swine (P=0.24). These values are consistent with measures of coronary perivascular adipocyte diameter ( Figure 1C ; average, 66±2 μm; n=2) from human subjects with evidence of coronary artery disease ( Figure 1F ). Verhoeff-van Gieson elastin stain demonstrated the presence of atheroma formation in obese ( Figure 1E ) compared with lean ( Figure 1D ) swine. These data are consistent with findings from other studies from our investigative team, which documented ≈15% to 20% stenosis of major coronary arteries (using intravascular ultrasound) in obese Ossabaw swine. [30] [31] [32] Immunostaining for CD163, a marker for cells of the monocyte/macrophage lineage, 33 revealed prominent staining in the medial layer of obese arteries ( Figure 1I ) with only modest staining evident in lean arteries ( Figure 1H ) relative to isotype control ( Figure 1G ). These findings are consistent with previous reports of inflammation in coronary arteries from obese swine. 34
Lean and Obese PVAT Attenuate Coronary Vasodilation
To initially examine the effects of PVAT on vasodilation, coronary arteries cleaned of surrounding PVAT from lean and obese swine were incubated with or without a known quantity of coronary PVAT (0.3 g) from the same animal for 30 minutes ( Figure II in the online-only supplement). Arteries were then preconstricted with the thromboxane A 2 mimetic U46619 (1 μmol/L). Active tension development of control arteries to U46619 (1 μmol/L) in the absence of PVAT averaged 9.01±0.41 g in lean and 10.20±0.61 g in obese arteries (P=0.09). In arteries treated with PVAT, active tension development averaged 9.61±0.42 g in lean and 9.88±0.53 g in obese arteries (P=0.68). Vasodilation to adenosine (30 μmol/L) was reduced ≈25% in obese ( Figure 2B ) compared with lean ( Figure 2A ) arteries in the absence of PVAT (P<0.001). The presence of PVAT significantly attenuated adenosine relaxation at concentrations >3 μmol/L in arteries from both lean and obese swine. Although maximal responses to adenosine were lower in obese arteries, the overall degree of PVAT inhibition on maximal adenosine-induced dilation (30 μmol/L) was similar in lean (≈31%) and obese (≈32%) arteries ( Figure 2A versus Figure 2B ). Preconstriction with KCl (60 mmol/L), which averaged 7.19±0.22 g in lean and 8.27±0.90 g in obese arteries (P=0.36), essentially abolished dilation to adenosine in both lean and obese arteries. Additional experiments in endothelium-denuded coronary arteries demonstrated that adenosine-induced dilation was unaffected by removal of the endothelium in both control (P=0.94) and PVAT-treated (P=0.99) arteries. Denudation was confirmed in these studies by <15% relaxation to bradykinin (1 mmol/L).
Lean Coronary PVAT Inhibits K Ca and K V 7 Channels
The contribution of K Ca channels to coronary vasodilation in lean and obese hearts was examined by comparing responses to the K Ca channel agonist NS-1619 (1-30 μmol/L). Overall responses to NS-1619 (30 μmol/L) were reduced ≈30% in obese compared with lean control arteries in the absence of PVAT (P=0.01; Figure 3A versus Figure 3B ). Compared with control responses, the addition of PVAT attenuated dilator responses to the NS-1619 (30 μmol/L) by ≈30% in lean arteries (P<0.001; Figure 3A ). In contrast, NS-1619-mediated dilation was unaffected by the addition of PVAT in obese arteries (P=0.90; Figure 3B ).
Nonstandard Abbreviation and Acronym
PVAT perivascular adipose tissue To investigate the role of K V 7 channels in coronary vasodilation, responses to the K V 7 channel agonist L-364,373 (10 nmol/L-10 μmol/L) were examined in lean and obese arteries. Dilation to L-364,373 was significantly attenuated at doses >3 μmol/L in obese compared with lean control arteries in the absence of PVAT (P<0.05; Figure 3C versus Figure 3D ). The presence of PVAT attenuated L-364,373-mediated dilation (10 μmol/L) by ≈20% in lean arteries (P=0.02; Figure 3C ) but had no effect in obese arteries (P=0.98; Figure 3D ). Western blot analyses of Kv7 channel (KCNQ1) protein indicated that the abundance of KCNQ1 was not significantly different in lean versus obese coronary arteries (P=0.11; Figure 4A and 4C). Abundance of β actin was not significantly different in lean versus obese arteries (P=0.91), indicating equal protein loading between samples. 
Obese Coronary PVAT Inhibits K ATP Channels
Studies to investigate the effect of coronary PVAT on K ATP channel-mediated dilation were performed by comparing responses to the K ATP channel agonist cromakalim (30 nmol/L-1 μmol/L) in lean and obese arteries. Control responses to cromakalim (1 μmol/L) were not significantly different in lean versus obese arteries in the absence of PVAT (P=0.90; Figure 3E and 3F). The presence of coronary PVAT from the same animal had no effect on dilation to cromakalim (1 μmol/L) in lean arteries (P=0.57; Figure 3E ). In contrast, PVAT significantly attenuated dilation to cromakalim in obese arteries (P=0.02; Figure 3F ). Western blot analyses show that abundance of K ATP channel pore-forming unit (K ir 6.1) protein was not different in obese compared with lean arteries (P=0.40; Figure 4B and 4D). Abundance of β actin was not significantly different in lean versus obese arteries (P=0.34), indicating equal protein loading between samples.
Differential Effects of Lean Versus Obese Coronary PVAT
To evaluate the specific effects of lean versus obese PVAT on K + channel function, independent of differences in coronary artery responsiveness, control coronary arteries (cleaned of PVAT) from lean swine were incubated with known quantities of PVAT (0.3 g) from either lean or obese swine euthanized on the same day. In contrast to the inhibitory effects of lean PVAT, obese PVAT had no effect on relaxation to NS-1619 (30 μmol/L) or L-364,373 (10 μmol/L) in lean arteries (P=0.40; Figure 5A and P=0.10; Figure 5B ). Alternatively, obese PVAT significantly attenuated relaxation to cromakalim (1 μmol/L; P<0.001; Figure 5C ), whereas lean PVAT had no effect (P=0.57). On the basis of previous findings, 12 additional proof-ofprinciple studies were performed to investigate the effects of calpastatin (10 μmol/L) on coronary vasodilation. Incubation with calpastatin significantly attenuated vasodilation to adenosine (from 3 μmol/L to 10 μmol/L) in lean arteries cleaned of PVAT (P=0.001; Figure 6A ). In contrast, exposure to calpastatin had no effect on adenosine dilation in obese arteries cleaned of PVAT (P=0.30; Figure 6B ).
Discussion
This investigation was designed to delineate the effects of lean and obese coronary PVAT on end-effector mechanisms of coronary vasodilation and to identify potential factors involved. The major new findings of this study are (1) diameters of adipocytes in epicardial coronary PVAT are similar in lean and obese swine; (2) factors derived from lean and obese coronary PVAT attenuate vasodilation in response to adenosine; (3) lean coronary PVAT inhibits K Ca and K V 7 channel-mediated dilation but has no effect on K ATP channel-mediated dilation in lean arteries; (4) coronary vasodilation to K Ca and K V 7 channel activation is impaired in obese relative to lean arteries in the absence of PVAT; (5) obese PVAT has no effect on K Ca or K V 7 channel activation in obese arteries; (6) obese PVAT inhibits K ATP channel-mediated vasodilation in both lean and obese coronary arteries; and (7) calpastatin attenuates coronary vasodilation to adenosine in lean but not in obese arteries. These findings provide novel evidence that lean and obese PVAT-derived factors attenuate coronary vasodilation via differential inhibition of K + channels and implicate a mechanistic link between alterations in PVAT-derived factors, such as calpastatin and diminished functional expression of coronary K + channels in the setting of obesity.
Although the ability of PVAT to produce transferrable factors that influence the vasculature is well established, current understanding about the nature of this effect in specific adipose tissue depots remains rather limited. Although the majority of studies on peripheral (noncardiac) PVAT support the production of adipose-derived relaxing factor(s) and an overall anticontractile effect, [17] [18] [19] [20] [21] [22] [35] [36] [37] [38] recent data indicate that coronary PVAT is unique relative to these other adipose depots both in its expression profile and effects on the vasculature. 6, 10, 12 In particular, factors derived from coronary PVAT have been found to attenuate endothelial-dependent dilation and potentiate coronary artery contractions, especially in the setting of obesity. [5] [6] [7] 12 Other studies in lean or hypercholesterolemic swine show little/no anticontractile effect of coronary PVAT in response to endothelin-1, angiotensin II, or the thromboxane A2 mimetic U46619. 6, 39, 40 Results from this study further support the distinct vascular effects of coronary PVAT in that lean and obese coronary PVAT significantly attenuate coronary vasodilator responses to adenosine. This impaired dilator response is directly related to effects of PVAT-derived factors on smooth muscle K + channels because adenosine-induced dilation was unaffected by endothelial denudation and was essentially abolished by preconstriction with KCl (Figure 2A and 2B) . Inhibitory effects of PVAT on K + channels have significant (patho)physiological implications as previous studies have clearly demonstrated the contribution of K V and K ATP channels to the regulation of coronary microvascular tone 29, 41 and K Ca channels in endothelial-dependent dilation. 42, 43 These findings provide novel evidence that lean and obese PVAT have distinct inhibitory effects on specific K + channel subtypes in lean and obese coronary arteries. Specifically, factors derived from lean coronary PVAT impair K Ca and K V 7 channel-mediated dilation, whereas factors derived from obese coronary PVAT attenuate K ATP channel-mediated dilation ( Figure 3) . The lack of effect of obese coronary PVAT on K Ca and K V 7 channels was observed in both obese ( Figure 3 ) and lean ( Figure 5 ) coronary arteries and is thus not related to intrinsic differences in smooth muscle phenotype of lean versus obese swine. Therefore, the cross-over studies in which lean arteries (ie, with normal vascular smooth muscle function) were incubated with lean and obese PVAT, strongly support that lean and obese PVAT-derived factors differentially affect K Ca , K V 7, and K ATP channels. This distinction is important because we found that coronary vasodilation in response to K Ca and K V 7 channel agonists is attenuated in obese relative to lean arteries in the absence of PVAT (Figure 3 ). These data are consistent with previous work from our laboratory and others, which demonstrated the functional downregulation of BK Ca and K V channels in the coronary circulation 24 suggest the potential for PVAT-derived factors to contribute to the initiation and progression of coronary vascular dysfunction in the setting of obesity.
There are several potential mechanisms that could contribute to the effects of PVAT-derived factors on coronary K + channels. In particular, it does not seem that differences in K + channel expression levels are responsible for the divergent effects of PVAT because Western analyses revealed similar levels of K V 7 (KCNQ1) and K ATP (K ir 6.1) channels in coronary arteries of lean and obese swine ( Figure 4 ). Previous studies from our group also found augmented expression of BK Ca channel subunits in coronary arteries of obese swine. 25 However, it is possible that expression of other channel subtypes or subunits could be altered in the setting of obesity. The potential for direct effects of PVAT-derived factors on specific coronary K + channels is supported by previous evidence that NS-1619, L-364,373, and cromakalim directly open K Ca , K V , and K ATP channels (ie, without activating transmembrane signaling pathways) because these agonists have been shown to bind to sites on channel subunits and increase the open probability of excised membrane patches. [47] [48] [49] In addition, cellular signaling pathways also influence the response of these K + channels to their respective agonists. For example, ischemic stimuli and Rho kinase signaling influence the response of K Ca channels to NS-1619, 50, 51 whereas the effects of L-364,373 on K V 7 channels may intersect with extracellular signal-regulated kinase signaling 52 and protein kinase C alters the K ATP channel response to cromakalim. 53 Therefore, it is possible that cellular signaling, including post-translational modifications, such as phosphorylation, influences the response of vascular smooth muscle K + channel activation in the presence of PVAT. 54 Such effects are in line with previous studies from our laboratory which demonstrated that coronary PVAT influences both protein kinase C and Rho kinase signaling. 6, 12 Whether coronary PVAT-derived factors interact with K + channels directly or influence their function indirectly through intracellular signaling pathways warrants further investigation.
Identification of the precise factors responsible for the vascular effects of coronary PVAT remains a daunting task. Recent studies by the Weintraub laboratory have established that adipocytes from human coronary PVAT have a distinct phenotype and exhibit elevated expression of proinflammatory genes and genes associated with angiogenesis, coagulation, and vascular morphology. 9, 10, 55, 56 Evidence of macrophage infiltration ( Figure 1I ) and atheroma formation ( Figure 1E ) in obese arteries support a potential role for inflammatory cross-talk between PVAT and the artery wall in the pathogenesis of atherosclerosis. A previous global proteomic assessment revealed the upregulation of proteins associated with cellular growth, proliferation, and movement in obese versus lean coronary PVAT from swine. 12 These differences seem to be independent of gross changes in morphology because similarities in adipocyte diameter were found between lean and obese PVAT ( Figure 1A and 1B) . Of particular interest is the endogenous calpain inhibitor, calpastatin, which we have shown to be significantly elevated in supernatant of obese coronary PVAT and to dose-dependently augment coronary artery contractions. 12 Findings from the current investigation further support that calpastatin is capable of mimicking the effects of coronary PVAT in that it acts to impair smooth muscle dilation in response to adenosine in lean coronary arteries ( Figure 6A ). The loss of this effect in obese coronary arteries ( Figure 6B) is consistent with the lack of effect of obese PVAT on K Ca and K V 7 channelmediated dilation in obese arteries ( Figure 3B and 3D) , and suggests that chronic local exposure of the coronary circulation to factors, such as calpastatin could contribute to the impairment of smooth muscle function in the setting of obesity.
It is important to recognize that although a differential effect of lean versus obese PVAT on vascular function was demonstrated in lean, healthy arteries, the effect of lean PVAT on obese arteries was not examined in this investigation. In addition, findings of this study were produced after short-term (≈30 minutes) exposure to PVAT ex vivo. Thus, a critical question remains as to whether chronic exposure of the coronary vasculature to the PVAT milieu directly contributes to the altered functional expression of K + channels in the setting of obesity. We propose that as the severity of obesity and other cardiovascular risk factors (insulin resistance, hypercholesterolemia, and hypertension) progresses, changes in the secretion profile of coronary PVAT adversely influences the function and expression of coronary ion channels. However, the extent to which phenotypic alterations in coronary PVAT causally contribute to mechanistic alterations in the obese coronary circulation merits further study.
In summary, these findings demonstrate that although coronary perivascular adipocytes from lean and obese swine share similar morphology, lean and obese PVAT-derived factors impair vasodilation via differential inhibition of vascular smooth muscle K + channels. Specifically, our data are the first to demonstrate that lean coronary PVAT attenuates K Ca and K V 7 channel-mediated dilation, whereas obese coronary PVAT impairs K ATP channel-mediated dilation. These results further support the paradigm of distinct outside-to-inside signaling influences of coronary PVAT and that alterations in specific factors, such as calpastatin are capable of contributing to the initiation or progression of smooth muscle dysfunction in the setting of obesity. 
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